• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Lansoprol 30mg 28 capsules — Made in Turkey — Free Delivery

    Lansoprol 30mg 28 capsules — Made in Turkey — Free Delivery


    Brand: Nobel Ilac San. Ve Tic. A.S.
    Product Code: Lansoprol
    Availability: In Stock
    $21.42
    Add to Cart

    Pharmacological properties

    Lanzoprazole inhibits the activity of the n + / k + -atphase of the proton pump in the parietal cells of the gastric mucosa. thus, lansoprazole inhibits the final stage of gastric acid formation, reduces the amount and acidity of gastric juice, as a result of which its harmful effect on the mucous membrane is reduced.
    The degree of suppression is determined by the dose and duration of treatment. Even a single dose of 30 mg of lansoprazole inhibits gastric acid secretion by 70–90%. The action occurs within 1 or 2 hours and lasts throughout the day.
    Lanzoprazole is absorbed in the intestine. In healthy patients, when taking 30 mg of lansoprazole, Cmax in blood plasma is 0.75–1.15 mg / l and is achieved within 1.5–2 hours. Cmax in blood plasma and bioavailability depend on the individual characteristics of the patient and do not change depending on from the frequency of taking the preparation.
    The binding of the preparation to blood plasma proteins is 98%.
    Lanzoprazole is excreted from the body with bile and urine (only in the form of metabolites - lansoprazole sulfone and hydroxylanzoprazole), while 21% of the preparation dose is excreted in the urine per day. T½ is 1.5 hours.
    T½ increases in patients with severe liver dysfunction and in patients over the age of 69 years. In patients with impaired renal function, the absorption of lansoprazole is practically unchanged.

    Indications

    Peptic ulcers of the stomach and duodenum, including those associated with the intake of NSAIDs, gastroesophageal reflux disease, Zollinger-Ellison syndrome, for the eradication of helicobacter pylori (in combination with antibiotics).

    Application

    Adults are taken internally. usually the dose is 30 mg 1 time per day 30-40 minutes before meals, the capsules are taken whole without chewing, drinking 15-200 mg of water. if this is not possible, the capsule can be opened and dissolved in a small amount of apple juice (approximately 1 full spoon) and swallowed immediately without chewing. the same procedure must be carried out if the preparation is administered through a nasogastric tube.
    The question of dosage and duration of treatment is decided by the doctor, depending on the clinical situation and the nature of the course of the disease.
    The maximum daily dose is 60 mg; for patients with impaired liver function - 30 mg. In patients with Zollinger-Ellison syndrome, doses may be increased.
    If it is necessary to take 2 daily doses, the patient should take one before breakfast, the second before dinner.
    If the patient does not take the preparation at the appointed time, he should take it as soon as possible. If there is little time left before the next dose, the patient should not take a double dose.
    Duodenal ulcer: the dose of the preparation for the treatment of active ulcers is 30 mg once a day for 2-4 weeks.
    The dose for the treatment of ulcers caused by taking NSAIDs is 30 mg once a day. Duration of treatment is 4–8 weeks.
    Peptic gastric ulcer: the dose of the preparation for the treatment of active ulcers is 30 mg once a day for 8 weeks. The dose for the treatment of ulcers caused by taking NSAIDs is 30 mg once a day for 4-8 weeks.
    Gastroesophageal reflux disease: in moderate and severe forms of esophagitis, the recommended dose is 30 mg once a day for 4 weeks. If erosive esophagitis is not cured within 4 weeks, the duration of treatment can be doubled.
    The dose for long-term prevention of recurrence of erosive esophagitis is 30 mg once a day. The safety and efficacy of lansoprazole therapy has been confirmed for a 12-month dose.
    Zollinger-Ellison syndrome: the dose of the preparation is selected so that the basal acid secretion does not exceed 10 mmol / h. The recommended starting dose is 60 mg 1 time per day before breakfast. If the patient is taking doses higher than 120 mg, then he should take the first half of the daily dose before breakfast, and the second half before dinner. Treatment lasts until the clinical symptoms disappear.
    Helicobacter pylori eradication: the dose is 30 mg 2 times a day (before breakfast and dinner). The patient should take the preparation together with antibiotics according to the approved scheme for 1-2 weeks.
    Renal and hepatic impairment. Patients with mild to moderate hepatic and renal impairment do not require dose adjustment. Patients with severely impaired liver function should take the minimum effective dose, but not more than 30 mg / day.
    Elderly patients. No dose adjustment is required when using the preparation.

    Contraindications

    Hypersensitivity to lansoprazole or any other component of the preparation. During pregnancy and breastfeeding. childhood.

    Side effects

    During treatment, adverse reactions were frequently reported such as abdominal pain, diarrhea, nausea, most often diarrhea. also headaches were reported in more than 1% of cases. additional adverse reactions that were detected in 1% of patients who participated in internal clinical trials and in the post-marketing period are as follows.
    The body as a whole: anaphylactoid reactions, asthenia, fatigue, candidiasis, chest pain (not always specific), edema, fever, flu-like syndrome, bad breath, infections (not always nonspecific), weakness.
    From the side of the cardiovascular system: angina pectoris, cerebrovascular changes, hypertension, arterial hypotension, myocardial infarction, palpitations, shock (circulatory failure), vasodilation.
    From the gastrointestinal tract: anorexia, cardiospasm, cholelithiasis, constipation, vomiting, hepatotoxicity, jaundice, hepatitis, esophageal candidiasis, gastrointestinal tract, dry mouth, thirst, dyspepsia, dysphagia, belching, esophageal stenosis, esophageal ulcer, change in the color of causal , stomach polyps, gastroenteritis, colitis, gastrointestinal hemorrhages, vomiting of blood, increased or decreased appetite, increased salivation, melena, rectal hemorrhages, stomatitis, taste disorders, glossitis, pancreatitis, tenesmus, ulcerative colitis.
    From the endocrine system: diabetes mellitus, goiter, hyperglycemia / hypoglycemia.
    From the blood and lymphatic system: anemia, hemolysis, agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, eosinophilia, thrombotic and thrombocytopenic purpura.
    From the musculoskeletal system and connective tissue: arthritis / arthralgia, musculoskeletal pain, myalgia.
    From the nervous system: agitation, amnesia, agitation, apathy, depression, impaired consciousness, vertigo, hallucinations, hemiplegia, hostility, fear, decreased / increased libido, nervousness, insomnia, drowsiness, tremors, paresthesias, thought disturbances, confusion.
    From the respiratory system: asthma, bronchitis, increased cough, shortness of breath, epistaxis, pulmonary bleeding, hiccups, pneumonia, inflammation / infection of the upper respiratory tract, pharyngitis, rhinitis.
    Skin and subcutaneous tissue disorders: angioedema, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema polyform, acne, facial flushing, alopecia, itching, rashes, urticaria, purpura, petechiae, hyperhidrosis, photosensitivity.
    From the senses: blurred vision, deafness, eye pain, change in taste, tinnitus, visual field defects, speech disorders, otitis media.
    From the genitourinary system: menstrual disorders, albuminuria, breast enlargement / gynecomastia, breast tenderness, glucosuria, hematuria, impotence, kidney stones, urinary retention.
    Combination therapy with amoxicillin and clarithromycin. In clinical trials, when carrying out combination therapy of lansoprazole with amoxicillin and clarithromycin, there are no specific side effects characteristic of combination therapy. Adverse reactions resulting from combination therapy are characteristic of lansoprazole, amoxicillin and clarithromycin.
    The most common adverse reactions in patients receiving triple therapy (lansoprazole / clarithromycin / amoxicillin) for 14 days were diarrhea, headache, and taste changes. There were no differences in the incidence of adverse reactions during triple therapy for 10 and 14 days. There were no differences in the manifestations of adverse reactions during triple and dual therapy. The most common adverse reactions during dual therapy of lansoprazole with amoxicillin are diarrhea and headache.
    Adverse reactions were not long-term and did not require discontinuation of treatment.
    Laboratory changes. Indicators of liver dysfunction, increased levels of ALT, AST, ALP, creatinine, globulins, gammaglutamyl transpeptidase, increase / decrease in the level of leukocytes, violation of the albumin / globulin ratio, change in the number of erythrocytes, hyperbilirubinemia, eosinophilia, hyperlipidemia, increase / decrease in electrolyte levels, increase / decrease Cholesterol, an increase in glucocorticoids, an increase in LDL cholesterol, an increase / decrease in platelets, an increase in gastrin levels, a positive occult blood test. In urine - albuminuria, glucosuria, hematuria.
    In patients receiving lansoprazole, at the end of treatment, an increase in the level of liver enzymes more than 3 times higher than the upper limit of normal was reported. One of these patients did not develop jaundice during treatment. When carrying out combination therapy (lansoprazole with clarithromycin and amoxicillin) and lansoprazole with amoxicillin, there are no changes in laboratory parameters specific to combination therapy.

    special instructions

    Before prescribing the preparation lansoprol, the possibility of malignant neoplasms in the stomach and esophagus should be excluded.
    When conducting combination therapy with clarithromycin and amoxicillin, the warnings regarding the use of these preparations should be read in the instructions for use of these preparations . With the use of antibacterial agents, pseudomembranous colitis, sometimes life-threatening, may occur. Therefore, it is important to consider this when patients have diarrhea. You should also pay attention before starting the use of amoxicillin and clarithromycin for a history of hypersensitivity reactions to penicillins, cephalosporins and other allergens.
    In patients with renal insufficiency, blood protein binding is reduced by 1–1.5%. In patients with varying degrees of chronic hepatic insufficiency, T½ from blood plasma increases from 1.5 to 3.2–7.2 hours. In patients with severe hepatic insufficiency, the dose of the preparation should be reduced.
    Elderly patients. Ulcer treatment in elderly patients practically does not differ from that in younger patients. Adverse reactions and laboratory changes in the elderly are the same as in younger patients.
    During pregnancy and breastfeeding. During pregnancy and lactation, the preparation is not used. If necessary, use of the preparation should stop breastfeeding.

    Interactions

    Lansoprazole is metabolized by the cytochrome p450 system, especially cyp 3a and cyp 2c19. studies conducted with lansoprazole do not show sufficient clinical interaction with other preparations metabolized by the cytochrome p450 system (warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisolone, diazepam, clarithromycin or terfenadine). these preparations are metabolized by the cytochrome p450 system, including cyp 1a2, cyp 2c 9, cyp 2c19, cyp 2d6, and cyp 3a. with the simultaneous use of lansoprazole with theophylline (cyp 1a2, cyp 3a), there is a moderate increase (10%) the clearance of theophylline, but the clinical significance of their interactions is unlikely, however, to maintain clinically effective concentrations of theophylline in individual patients, a dose adjustment of theophylline is required at the beginning or upon termination of treatment lansoprazole.
    There are no clinical manifestations of interactions with amoxicillin.
    In a cross-sectional study conducted with the administration of lansoprazole 30 mg, omeprazole 20 mg and the simultaneous use of sucralfate 1 g, the simultaneous use of sucralfate decreases the absorption of proton pump inhibitors and the bioavailability of lansoprazole and omeprazole by 17 and 16%, respectively. Therefore, proton pump inhibitors should be taken 30 minutes before taking sucralfate. With the simultaneous use of antacids and lansoprazole in a clinical study, there is no effect on their action. Lansoprazole causes prolonged inhibition of gastric secretion, so it is theoretically possible that lansoprazole can affect the bioavailability of preparations for which the absorption has a pH value (ketoconazole, ampicillin esters, iron salts, digoxin).
    Lansoprazole, like other proton pump inhibitors, reduces the concentration of atazanavir (an inhibitor of HIV protease), the absorption of which depends on gastric acidity, and therefore may affect the therapeutic effect of atazanavir and the development of resistance to HIV infection.
    In clinical studies in healthy volunteers, it was shown that lansoprazole does not affect the pharmacokinetics of warfarin and prothrombin time. An increase in INR and prothrombin time can lead to bleeding and even death.
    Tacrolimus With the simultaneous use of lansoprazole and tacrolimus, the concentration of tacrolimus in the blood may increase, especially in patients who underwent transplantation.

    Overdose

    There are no reported cases of lansoprazole overdose. a single dose of the preparation at a dose of 600 mg was not accompanied by clinical manifestations of an overdose. however, in case of an overdose, an increase in the severity of adverse reactions is possible.
    Treatment. There is no specific antidote. Hemodialysis is ineffective. To reduce the absorption of the preparation, it is necessary to take activated charcoal. In case of taking an excessive dose, symptomatic and supportive therapy is carried out.

    Storage conditions

    Store at a temperature not exceeding 25 ° c.

    There are no reviews for this product.
    VEV Healthcare Store © 2017